ArticleHepatology international2020
Development and validation of a clinical and laboratory-based nomogram to predict nonalcoholic fatty liver disease.
Article in Hepatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Pooled it
- Diagnostic accuracy of the visceral adiposity index in patients with metabolic-associated fatty liver disease: a meta-analysis.Lipids in health and disease · 2022Pooled it
- The triglyceride and glucose index and risk of nonalcoholic fatty liver disease: A dose-response meta-analysis.Frontiers in endocrinology · 2022Pooled it
- Surveying the features of screening strategies for non-alcoholic fatty liver disease: A scoping review.Journal of education and health promotion · 2026Review
- Study of association and diagnostic utility of novel anthropometric and lipid indices for nonalcoholic fatty liver disease: A hospital-based study.Journal of family medicine and primary care · 2025Article
- Association Between Visceral Adiposity and the Prediction of Hepatic Steatosis and Fibrosis in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).Journal of clinical medicine · 2025Article
- Establishment and evaluation of a novel practical tool for the screening of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus.Frontiers in nutrition · 2025Article
- ISIFrontiers in medicine · 2025Article
- LASSO-derived model for the prediction of lean-non-alcoholic fatty liver disease in examinees attending a routine health check-up.Annals of medicine · 2024Article
- Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease.United European gastroenterology journal · 2024Review
- Nomogram for predicting the risk of nonalcoholic fatty liver disease in older adults in Qingdao, China: A cross-sectional study.Asia Pacific journal of clinical nutrition · 2024Article
- Development and Validation of a Risk Prediction Model for NAFLD: A Study Based on a Physical Examination Population.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Non-alcoholic fatty liver disease risk prediction model and health management strategies for older Chinese adults: a cross-sectional study.Lipids in health and disease · 2023Article
- Development and validation of a nomogram for predicting metabolic-associated fatty liver disease in the Chinese physical examination population.Lipids in health and disease · 2023Article
- Assessing the clinical utility of major indices for nonalcoholic fatty liver disease in East Asian populations.Biomarkers in medicine · 2023Review
- SFI, a sex hormone binding globulin based nomogram for predicting non-alcoholic fatty liver disease in the Chinese population.Frontiers in endocrinology · 2023Article
- The roles of hepatokine and osteokine in liver-bone crosstalk: Advance in basic and clinical aspects.Frontiers in endocrinology · 2023Review
- Development and validation of a new nomogram to screen for MAFLD.Lipids in health and disease · 2022Article
- Comparison of the diagnostic value between triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio in metabolic-associated fatty liver disease patients: a retrospective cross-sectional study.Lipids in health and disease · 2022Article
- Role of serum hyaluronic acid in predicting necroinflammatory activity of the nonalcoholic fatty liver disease.Hepatology forum · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
aimNonalcoholic fatty liver disease (NAFLD) is becoming the leading cause of chronic liver disease in China. The early identification and management of patients at risk are essential. We aimed to develop a novel clinical and laboratory-based nomogram (CLN) model to predict NAFLD with high accuracy.
methodsWe designed a retrospective cross-sectional study and enrolled 21,468 participants (16,468 testing and 5000 validation). Clinical information and laboratory/imaging results were retrieved. Significant variables independently associated with NAFLD were identified by a logistic regression model, and a NAFLD prediction CLN was constructed. The CLN was then compared with four existing NAFLD-related prediction models: the fatty liver index (FLI), the hepatic steatosis index (HSI), the visceral adiposity index (VAI) and the triglycerides and glucose (TyG) index. Area under the receiver operator characteristic curve (AUROC) and decision curve analysis (DCA) were performed.
resultsA total of 6261/16,468 (38.02%) and 1759/5000 (35.18%) participants in the testing and validation datasets, respectively, had ultrasound-proven NAFLD. Six variables were selected to build the CLN: body mass index (BMI), diastolic blood pressure (DBP), uric acid (UA), fasting blood glucose (FBG), triglyceride (TG), and alanine aminotransferase (ALT). The diagnostic accuracy of the CLN for NAFLD (AUROC 0.857, 95% CI 0.852-0.863) was significantly superior to that of the FLI (AUROC 0.849, 95% CI 0.843-0.855), the VAI (AUROC 0.752, 95% CI 0.745-0.760), the HSI (AUROC 0.828, 95% CI 0.822-0.834), and the TyG index (AUROC 0.774, 95% CI 0.767-0.781) (all p < 0.001). DCA confirmed the clinical utility of the CLN.
conclusionsThis physical examination and laboratory test-based, nonimage-assisted novel nomogram has better performance in predicting NAFLD than the FLI, the VAI, the HSI and the TyG index alone. This model can be used as a quick screening tool to assess NAFLD in the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.